These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 29055780)

  • 1. Pregnancy outcomes associated with extended use of the 52-mg 20 μg/day levonorgestrel-releasing intrauterine system beyond 60 months: A chart review of 776 women in Brazil.
    Bahamondes L; Fernandes A; Bahamondes MV; Juliato CT; Ali M; Monteiro I
    Contraception; 2018 Mar; 97(3):205-209. PubMed ID: 29055780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrauterine device continuation rates and reasons for discontinuation in a Central European clinic with a high standard of care and ultrasound follow-up: a retrospective cohort study.
    Bachofner M; Blickenstorfer K; Hutmacher J; Wehrle L; Leeners B; Merki-Feld G
    Eur J Contracept Reprod Health Care; 2018 Dec; 23(6):407-414. PubMed ID: 30628516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case series on the use of levonorgestrel 52 mg intrauterine system after organ transplant.
    Juliato CRT; Stahlschmidt P; Fernandes A; Monteiro I; Bahamondes L
    Contraception; 2018 Sep; 98(3):252-254. PubMed ID: 29746814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimated disability-adjusted life years averted by long-term provision of long acting contraceptive methods in a Brazilian clinic.
    Bahamondes L; Bottura BF; Bahamondes MV; Gonçalves MP; Correia VM; Espejo-Arce X; Sousa MH; Monteiro I; Fernandes A
    Hum Reprod; 2014 Oct; 29(10):2163-70. PubMed ID: 25085802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Menstrual characteristics and ultrasonographic uterine cavity measurements predict bleeding and pain in nulligravid women using intrauterine contraception.
    Kaislasuo J; Heikinheimo O; Lähteenmäki P; Suhonen S
    Hum Reprod; 2015 Jul; 30(7):1580-8. PubMed ID: 25990577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls.
    Bahamondes L; Brache V; Meirik O; Ali M; Habib N; Landoulsi S;
    Hum Reprod; 2015 Nov; 30(11):2527-38. PubMed ID: 26409014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant.
    Ali M; Akin A; Bahamondes L; Brache V; Habib N; Landoulsi S; Hubacher D;
    Hum Reprod; 2016 Nov; 31(11):2491-2498. PubMed ID: 27671673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of levonorgestrel-releasing intrauterine system (LNG-IUS) 52 mg versus other long-acting reversible contraceptives for contraception in Spain.
    Conde JCQ; Parra Ribes I; Perelló-Capo J; Lobo Abascal P; García IC; Andeyro García M; Gutiérrez Alés J; Herrero Conde M; Rius Tarruella J; Espinós Lafuente B
    Eur J Contracept Reprod Health Care; 2024 Oct; 29(5):224-232. PubMed ID: 38989683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a new, low-dose levonorgestrel intrauterine contraceptive system over 5 years of use.
    Gemzell-Danielsson K; Apter D; Dermout S; Faustmann T; Rosen K; Schmelter T; Merz M; Nelson A
    Eur J Obstet Gynecol Reprod Biol; 2017 Mar; 210():22-28. PubMed ID: 27930941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in continuation rates and early removal between contraceptive and therapeutic use of the levonorgestrel-releasing intrauterine system 52 mg.
    Teunissen AM; Merry AHH; Devies IEC; Roumen FJME
    Eur J Contracept Reprod Health Care; 2019 Dec; 24(6):449-456. PubMed ID: 31696740
    [No Abstract]   [Full Text] [Related]  

  • 11. Two years of intrauterine contraception with levonorgestrel and with copper: a randomized comparison of the TCu 380Ag and levonorgestrel 20 mcg/day devices.
    Sivin I; Stern J; Diaz J; Diaz MM; Faundes A; el Mahgoub S; Diaz S; Pavez M; Coutinho E; Mattos CE
    Contraception; 1987 Mar; 35(3):245-55. PubMed ID: 3111785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control - a randomized controlled trial.
    Papaikonomou K; Kopp Kallner H; Söderdahl F; Gemzell-Danielsson K
    Hum Reprod; 2018 Nov; 33(11):2002-2009. PubMed ID: 30295731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A single-arm phase III study exploring the efficacy and safety of LNG-IUS 8, a low-dose levonorgestrel intrauterine contraceptive system (total content 13.5 mg), in an Asia-Pacific population.
    Fan G; Kang S; Ren M; Weisberg E; Lukkari-Lax E; Roth K; Shin S
    Contraception; 2017 Apr; 95(4):371-377. PubMed ID: 27913229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of a 5-year contraceptive trial in parous and nulliparous women with a new LNG-IUS.
    Wildemeersch D; Goldstuck ND; Jackers G
    Gynecol Endocrinol; 2017 Mar; 33(3):223-226. PubMed ID: 28084114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormonal and intrauterine methods for contraception for women aged 25 years and younger.
    Krashin J; Tang JH; Mody S; Lopez LM
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD009805. PubMed ID: 26280888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bleeding pattern difference between levonorgestrel intrauterine system and copper intrauterine devices inserted immediately post-abortion: a multicenter, prospective, observational cohort study in Chinese women.
    Chen X; Li Q; Wang X; Chen J; Lv W; Shi B; Wang H; Luo J; Li J
    Curr Med Res Opin; 2018 May; 34(5):873-880. PubMed ID: 29298525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of two cohorts of women who expulsed either a copper-intrauterine device or a levonorgestrel-releasing intrauterine system.
    Simonatto P; Bahamondes MV; Fernandes A; Silveira C; Bahamondes L
    J Obstet Gynaecol Res; 2016 May; 42(5):554-9. PubMed ID: 26817571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.
    Sturridge F; Guillebaud J
    Drug Saf; 1996 Dec; 15(6):430-40. PubMed ID: 8968696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative Risk of Cervical Neoplasms Among Copper and Levonorgestrel-Releasing Intrauterine System Users.
    Spotnitz ME; Natarajan K; Ryan PB; Westhoff CL
    Obstet Gynecol; 2020 Feb; 135(2):319-327. PubMed ID: 31923062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of levonorgestrel 52 mg intrauterine system compared to copper intrauterine device: a population-based cohort study.
    Bosco-Lévy P; Gouverneur A; Langlade C; Miremont G; Pariente A
    Contraception; 2019 Jun; 99(6):345-349. PubMed ID: 30871933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.